Mechanism of Action and Epitopes of Clostridium difficile Toxin B-neutralizing Antibody Bezlotoxumab Revealed by X-ray CrystallographyPeter Orth, Alex G. Therien, Fred Racine et al.|Journal of Biological Chemistry|2014Cited by 138
Broad Coverage of Genetically Diverse Strains of Clostridium difficile by Actoxumab and Bezlotoxumab Predicted by <i>In Vitro</i> Neutralization and Epitope ModelingLorraine D. Hernandez, Alex G. Therien, Fred Racine et al.|Antimicrobial Agents and Chemotherapy|2014Cited by 54
Elucidation of DnaE as the Antibacterial Target of the Natural Product, NargenicinRonald E. Painter, Katherine Young, Gregory C. Adam et al.|Chemistry & Biology|2015Cited by 40
Rapid Evolution of a Fragment-like Molecule to Pan-Metallo-Beta-Lactamase Inhibitors: Initial Leads toward Clinical CandidatesMihirbaran Mandal, Haifeng Tang, Li Xiao et al.|Journal of Medicinal Chemistry|2022Cited by 27
Clostridium difficile toxin B CROP domain in complex with FAB domains of neutralizing antibody bezlotoxumabPeter Orth, Alex G. Therien, Le Xiao et al.|Unknown|2013Cited by 0